CoChat
Sign Up
Cited by 38Diabetes Management and ResearchDiabetes Management and EducationDiabetes Treatment and Management

Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology

Lucidi, Paola, Porcellati, Francesca, Bolli, Geremia B., Fanelli, Carmine G.·2018·Current Diabetes Reports
DOI 10.1007/s11892-018-1065-6
Open this paper in CoChat — free account

Abstract

Purpose of review In addition to assisting in achieving improved glucose control, continuous glucose monitoring (CGM) sensor technology may also aid in detection and prevention of hypoglycemia. In this paper, we report on the current scientific evidence on the effectiveness of this technology in the prevention of severe hypoglycemia and hypoglycemia unawareness.Recent findings Recent studies have found that the integration of CGM with continuous subcutaneous insulin infusion (CSII) therapy, a system known as sensor-augmented pump (SAP) therapy, very significantly reduces the occurrence of these conditions by providing real-time glucose readings/trends and automatically suspending insulin infusion when glucose is low (LGS) or, even, before glucose is low but is predicted to soon be low (PLGS). Initial data indicate that even for patients with type 1 diabetes treated with multiple daily injections, real-time CGM alone has been found to reduce both severe hypoglycemia and hypoglycemia unawareness. Closed loop systems (artificial pancreas) comprised of CGM and CSII without patient intervention to adjust basal insulin, which automatically reduce, increase, and suspend insulin delivery, represent a potential new option that is moving toward becoming a reality in the near future. Sensor technology promises to continue to improve patients' lives not only by attaining glycemic control but also by reducing hypoglycemia, a goal best achieved in conjunction with structured individualized patient education.

Integrity signals

Registry

Crossref · 10.1007/s11892-018-1065-6

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Other treatment options for patients with T2D such as metformin, glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors, pioglitazone, and sodium-glucose co-transporter-2 inhibitors show beneficial effects in reducing the risk of hypoglycemia.

    “Other treatment options for patients with T2D such as metformin, glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors, pioglitazone, and sodium-glucose co-transporter-2 inhibitors show in contrast beneficial effects in reducing the risk of hypoglycemia [ 56 ].”

    From Hypoglycemia Unawareness—A Review on Pathophysiology and Clinical Implications (2024) · cites this paper as [56]

  • Closed-loop systems reduce time spent in hypoglycemia.

    “It has been shown that closed-loop systems reduce time spent in hypoglycemia [ 56 , 66 ].”

    From Hypoglycemia Unawareness—A Review on Pathophysiology and Clinical Implications (2024) · cites this paper as [56]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Lucidi, P., Porcellati, F., Bolli, G. B., & Fanelli, C. G.
Affiliations
University of Perugia (IT)
Corresponding author
Fanelli, Carmine G.
ORCID
Venue
Current Diabetes Reports
Publisher
Springer Science and Business Media LLC
Published
2018-08-18
Volume
18
Issue
10
Pages
83-83
ISSN
  • 1534-4827 (ISSN-L)
  • 1539-0829
DOI
10.1007/s11892-018-1065-6
OpenAlex
W2885343258
Cited by
38
References
90
Citations by year
2026: 1 · 2025: 4 · 2024: 6 · 2023: 2 · 2022: 4 · 2021: 8 · 2020: 6 · 2019: 5 · 2018: 2
FWCI
0.81
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Current Diabetes Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
severe hypoglycemia, hypoglycemia unawareness, continuous glucose monitoring, sensor-augmented pump therapy, insulin pump therapy, low glucose suspend, predictive low glucose suspend, artificial pancreas, type 1 diabetes, multiple daily insulin injections, patient education
MeSH terms
Blood Glucose, Humans, Hypoglycemia, Insulin, Health Knowledge, Attitudes, Practice, Monitoring, Physiologic, Blood Glucose Self-Monitoring

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review